Literature DB >> 23130880

Mutation detection in Croatian patients with familial hypercholesterolemia.

Ivan Pećin1, Ros Whittall, Marta Futema, Jadranka Sertić, Zeljko Reiner, Sarah E A Leigh, Steve E Humphries.   

Abstract

Familial hypercholesterolemia (FH) is caused by mutations in the genes for LDLR, APOB or PCSK9, and identification of the causative mutation provides definitive diagnosis so that the patient can be treated, their relatives tested and, therefore, premature heart disease prevented. DNA of eight unrelated individuals with clinically diagnosed FH were analyzed using a High-Resolution Melting method (HRM) for the LDLR gene (coding region, promoter and intron/exon boundaries), the APOB gene (part exon 26) and the PCSK9 gene (exon7). Variations found were sequenced and the effect on function of confirmed variants examined using predictive algorithms. Gross deletions and insertions were analysed using MLPA. Three novel LDLR variants were found, p.(S470C), p.(C698R) and c.2312-2A>C. All were predicted to be pathogenic using predictive algorithms. Three previously reported disease-causing mutations were identified (p.(G20R), p.(N272T) and p.(S286R); the latter was also carried by a hypercholesterolaemic relative. One patient carried the pathogenic APOB variant p.(R3527Q). No large LDLR deletions nor insertions were found, neither were any PCSK9 variants identified. HRM is a sensitive method for screening for mutations. While the causative mutation has been identified in 88% of these clinically defined FH patients, there appears to be a high degree of allelic heterogeneity in Croatian patients.
© 2012 Blackwell Publishing Ltd/University College London.

Entities:  

Mesh:

Year:  2012        PMID: 23130880     DOI: 10.1111/j.1469-1809.2012.00735.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  7 in total

Review 1.  Management of patients with familial hypercholesterolaemia.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

Review 2.  Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.

Authors:  Ivan Pećin; Merel L Hartgers; G Kees Hovingh; Ricardo Dent; Željko Reiner
Journal:  Eur J Prev Cardiol       Date:  2017-06-23       Impact factor: 7.804

3.  Homoarginine Supplementation Prevents Left Ventricular Dilatation and Preserves Systolic Function in a Model of Coronary Artery Disease.

Authors:  Roman N Rodionov; Hoshimjon Begmatov; Natalia Jarzebska; Ketul Patel; Matthew T Mills; Zulaikha Ghani; Doreen Khakshour; Pankti Tamboli; Mitul N Patel; Mirette Abdalla; Maryann Assaf; Stefan R Bornstein; Jose Luis Millan; Stefanie M Bode-Böger; Jens Martens-Lobenhoffer; Norbert Weiss; Olga V Savinova
Journal:  J Am Heart Assoc       Date:  2019-07-15       Impact factor: 5.501

Review 4.  Molecular diagnosis methods in familial hypercholesterolemia.

Authors:  Valeriu Moldovan; Claudia Banescu; Minodora Dobreanu
Journal:  Anatol J Cardiol       Date:  2020-02       Impact factor: 1.596

Review 5.  PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.

Authors:  Qianyun Guo; Xunxun Feng; Yujie Zhou
Journal:  Front Genet       Date:  2020-09-23       Impact factor: 4.599

6.  Familial hypercholesterolemia mutations in Petrozavodsk: no similarity to St. Petersburg mutation spectrum.

Authors:  Tatiana Yu Komarova; Victoria A Korneva; Tatiana Yu Kuznetsova; Alexandra S Golovina; Vadim B Vasilyev; Michail Yu Mandelshtam
Journal:  BMC Med Genet       Date:  2013-12-27       Impact factor: 2.103

7.  Overexpression of tissue-nonspecific alkaline phosphatase (TNAP) in endothelial cells accelerates coronary artery disease in a mouse model of familial hypercholesterolemia.

Authors:  Filippo Romanelli; AnthonyMarco Corbo; Maryam Salehi; Manisha C Yadav; Soha Salman; David Petrosian; Omid J Rashidbaigi; Jesse Chait; Jes Kuruvilla; Maria Plummer; Ilian Radichev; Kenneth B Margulies; A Martin Gerdes; Anthony B Pinkerton; José Luis Millán; Alexei Y Savinov; Olga V Savinova
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.